Talphera Q2 FY26 net loss widens to $4.31 million; operating expenses rise to $3.92 million
TLPH•Clinical progress and market update
The NEPHRO CRRT study of nafamostat reached 75% enrollment; completion remains expected by year-end, with all target sites activated.
Draft 2026 KDIGO guidelines cited nafamostat as an acceptable CRRT anticoagulant; market research pegs 2027 U.S. CRRT procedures at 200,000.
Second-quarter results and expenses
Talphera posted a GAAP net loss attributable to common shareholders of $4.3 million, or $0.06 per share, in Q2 2026.
Combined R&D and SG&A expenses rose 5.41% to $3.9 million, driven by higher Niyad development costs on increased enrollment.
Cash and investments were $17.1 million at June 30, 2026.
